TY - JOUR
T1 - A novel method for objective quantification of apathy based on gaze and physiological reactivity to stimuli presented in a virtual reality environment
AU - Ravona-Springer, Ramit
AU - Koren, Or
AU - Galor, Noam
AU - Lapid, Michal
AU - Bahat, Yotam
AU - Fluss, Ronen
AU - Wilf, Meytal
AU - Zorani, Shlomit
AU - Rosenblum, Uri
AU - Beeri, Michal Schnaider
AU - Plotnik, Meir
N1 - Publisher Copyright:
© 2025 The Author(s). Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - INTRODUCTION: We developed a tool for objective quantification of apathy. METHODS: Participants (n = 97; 67 with cognitive impairment, 30 cognitively normal; mean age = 74.3 ± 6.2 years, 56.7% females) were exposed to emotional and cognitive stimuli in a virtual reality environment. Gaze metrics (time to first fixation [TTFF] and total fixation duration [TFD]) and autonomic nervous system (ANS) reactivity were measured. Apathy and depression were clinically assessed using the Lille Apathy Rating Scale short version and the Geriatric Depression Scale 15-item version, respectively. Cutoffs of ≥ –7 and ≥ 5 were used to define apathy and depression, respectively. RESULTS: The sample comprised 14 participants with apathy only, 9 with depression only, 10 with both, 63 with neither, and 1 with missing data. For all emotional stimuli, participants with apathy only showed longer TTFF (P = 0.039, effect sizes [ES] = 0.798), and shorter TFD (P = 0.023, ES = 0.578) compared to those without apathy or depression. ANS reactivity was not associated with apathy. DISCUSSION: Apathy is associated with decreased gaze engagement at emotional stimuli. Highlights: Apathy measurement via questionnaires is limited by subjectivity biases. Apathy measurement via questionnaires is limited by simplistic scoring. We present a novel method for objective measurement of apathy. Gaze characteristics reflect the emotional and cognitive components of apathy.
AB - INTRODUCTION: We developed a tool for objective quantification of apathy. METHODS: Participants (n = 97; 67 with cognitive impairment, 30 cognitively normal; mean age = 74.3 ± 6.2 years, 56.7% females) were exposed to emotional and cognitive stimuli in a virtual reality environment. Gaze metrics (time to first fixation [TTFF] and total fixation duration [TFD]) and autonomic nervous system (ANS) reactivity were measured. Apathy and depression were clinically assessed using the Lille Apathy Rating Scale short version and the Geriatric Depression Scale 15-item version, respectively. Cutoffs of ≥ –7 and ≥ 5 were used to define apathy and depression, respectively. RESULTS: The sample comprised 14 participants with apathy only, 9 with depression only, 10 with both, 63 with neither, and 1 with missing data. For all emotional stimuli, participants with apathy only showed longer TTFF (P = 0.039, effect sizes [ES] = 0.798), and shorter TFD (P = 0.023, ES = 0.578) compared to those without apathy or depression. ANS reactivity was not associated with apathy. DISCUSSION: Apathy is associated with decreased gaze engagement at emotional stimuli. Highlights: Apathy measurement via questionnaires is limited by subjectivity biases. Apathy measurement via questionnaires is limited by simplistic scoring. We present a novel method for objective measurement of apathy. Gaze characteristics reflect the emotional and cognitive components of apathy.
KW - apathy
KW - autonomic nervous system
KW - cognitive component of apathy
KW - cognitive impairment
KW - dementia
KW - emotional component of apathy
KW - gaze
KW - objective measurement
KW - physiological reactivity
KW - subjective measurement
KW - virtual reality
UR - http://www.scopus.com/inward/record.url?scp=85214676231&partnerID=8YFLogxK
U2 - 10.1002/dad2.70020
DO - 10.1002/dad2.70020
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 40061180
AN - SCOPUS:85214676231
SN - 2352-8729
VL - 17
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
M1 - e70020
ER -